Table 1.
Demographic and clinical characteristics of the patients
| Characteristics | Total (N = 51) | Remdesivir group (N = 25) | No remdesivir group (N = 26) | P |
|---|---|---|---|---|
| Male sex, n (%) | 47 (92.2) | 23 (92) | 24 (92.3) | >0.999 |
| Median (IQR) age (years) | 67 (59–75.5) | 64 (57–75) | 70 (63.3–76) | 0.313 |
| Interval between symptom onset and ICU admission, median (IQR) (days) | 10 (8–12) | 11 (8–13) | 9 (8–11) | 0.197 |
| Comorbidities, n (%) | ||||
| ischaemic heart disease | 7 (13.7) | 3 (12) | 4 (15.4) | >0.999 |
| congestive heart failure | 4 (7.8) | 0 (0) | 4 (15.4) | 0.110 |
| COPD | 3 (5.9) | 0 (0) | 3 (11.5) | 0.235 |
| diabetes mellitus | 7 (13.7) | 3 (12) | 4 (15.4) | >0.999 |
| chronic kidney disease | 4 (7.8) | 2 (8) | 2 (7.7) | >0.999 |
| hypertension | 28 (54.9) | 14 (56) | 14 (53.8) | 0.877 |
| Median (IQR) Charlson Comorbidity Index | 3 (1–4) | 2 (1–3) | 3 (3–4) | 0.131 |
| Laboratory values | ||||
| mean ± SD WBC/mm3 | 9246 ± 3500 | 9172 ± 3203 | 9318 ± 3826 | 0.883 |
| mean ± SD neutrophils/mm3 | 8040 ± 3342 | 7902 ± 3224 | 8173 ± 3511 | 0.775 |
| median (IQR) lymphocytes/mm3 | 600 (400–900) | 600 (500–830) | 550 (300–900) | 0.263 |
| median (IQR) platelets × 103/mm3 | 190 (153–245) | 192 (162–242) | 184 (145–247) | 0.578 |
| median (IQR) creatinine (mg/dL) | 1.04 (0.86–1.45) | 0.97 (0.89–1.24) | 1.11 (0.85–1.57) | 0.468 |
| median (IQR) ALT (U/L) | 45 (32.5–65.5) | 45 (26–67) | 45 (37.3–61.8) | 0.402 |
| median (IQR) AST (U/L) | 34 (25.5–53) | 34 (23–55) | 33.5 (27.5–43.8) | 0.671 |
| median (IQR) total bilirubin (mg/dL) | 0.9 (0.65–1.25) | 0.9 (0.7–1.2) | 0.8 (0.6–1.28) | 0.564 |
| median (IQR) LDH (U/L) | 473 (387–559) | 450 (342–510) | 542 (416–559) | 0.070 |
| mean ± SD CRP (mg/dL) | 20.5 ± 11.8 | 20.9 ± 13.8 | 20.2 ± 9.7 | 0.833 |
| Median (IQR) SOFA score at admission | 5 (4–6) | 4 (3–5) | 5 (4–6) | 0.037 |
| CRRT, n (%) | 25 (49) | 10 (40) | 15 (57.7) | 0.206 |
| Concomitant therapies, n (%) | ||||
| hydroxychloroquine | 33 (64.7) | 17 (68) | 16 (61.5) | 0.771 |
| lopinavir/ritonavir | 29 (56.9) | 15 (60) | 14 (53.8) | 0.657 |
| tocilizumab | 9 (17.6) | 7 (28) | 2 (7.7) | 0.075 |
Normally distributed continuous data are reported as mean ± SD. Non-normally distributed continuous data are reported as median and IQR.